

Index

A

- abacavir 106
- Aboriginal and Torres Strait Islanders *see*
- Indigenous Australians
- acquired immunodeficiency syndrome
see AIDS
- acute HIV infection *see* primary HIV infection
- acute retroviral syndrome 46–7, 50
- acute viral hepatitis 54–62
- and anxious patient management 59
 - clinical monitoring 57–9
 - contact tracing 59
 - diagnostic approach 55–6
 - key considerations 56
 - non-serological investigations 55–6
 - serological investigations 56
 - diagnostic and management
 - algorithm 58
 - epidemiology 54
 - exclusion from work 60
 - exposed person's immunity 60
 - hospital referral 59
 - incubation periods 54
 - opportunistic diagnosis and prevention strategies 59
 - outcomes 54, 55
 - post-exposure follow-up 61
 - post-exposure management 60
 - post-exposure prophylaxis 60–1
 - **prevention**
 - education and harm minimisation 62
 - immunisation 61–2
 - perinatal transmission 61
 - psychosocial issues 61
 - public health notification 59
 - source status 60
 - specific therapy 56–7
 - supportive therapy 56
 - symptoms and signs 54
 - *see also* hepatitis A (HAV); hepatitis B (HBV); hepatitis C (HCV)
- adefovir dipivoxil 24, 118, 121, 122
- adenoviral urethritis 11
- adenoviruses 11, 131, 136
- adherence to therapy 25, 108–9
- AIDS 63, 179
- body composition changes 69
 - risk of progression of HIV to 101
 - State/Territory notification requirements 183
- AIDS-indicator diseases 64, 101
- AIDS-related illness 109
- alanine aminotransferase (ALT) 24, 55, 56, 72, 76, 113, 114
- alcohol abuse, and HIV 103
- alcohol consumption, and HCV therapy 116
- alcoholic hepatitis 55
- alpha-1-antitrypsin deficiency 76, 112
- alpha-fetoprotein (AFP) 76
- amoebiasis 87
- anal sex 16, 29, 41
- anergy 65
- angiokeratomas 136, 137
- ano-genital lumps and bumps 87
- description and causes 135–6
 - diagnostic tests 136–7
 - differential diagnosis 136
 - initial treatment 137
 - treatment for specific STIs 137–8
- ano-genital rash 135
- ano-genital ulcer disease GUD) 87
- description and causes 133
 - diagnostic testing 136
 - differential diagnosis 133
 - initial treatment 133
 - and risk of HIV 23
 - treatment of specific STIs 135
- ano-genital warts 87, 135–6
- in chronic HIV infection 65
 - treatment 137
 - *see also* genital warts
- ano-rectal junction, diagnostic tests for STIs 135
- ano-rectal Pap smear ('CHAP' smear) 85–6
- ano-rectal syndromes 87
- description and causes 138
 - diagnostic tests 138–9
 - differential diagnosis 138
 - initial treatment 139
 - treatment for specific STIs 139
- anti-discrimination 155–6
- antibody testing *see* testing
- antiretroviral therapy (for HIV) 23–4, 36
- adherence issues 108–9
 - assessment of response to therapy 108
 - drug classes 23, 106, 107, 108
 - drug interactions 108
 - initiating 105–7
 - medications 106–7
 - primary HIV infection 49
 - psychosocial concerns 103
 - side effects 106–7, 108
 - treatment regimens 107–8

antiviral therapy	
• for chronic hepatitis B	24, 56–7, 118–19, 121–2
• for chronic hepatitis C	24–5, 72, 113–14, 118–19, 120–1
• for chronic viral hepatitis	117–22
• decision to treat	121
• shift to primary care	121
• side effects	121
• who should be treated?(HBV)	122
• who should be treated?(HCV)	120–1
aphthous mouth ulcers	66
arthropathy	76
ascites	34, 74
Asian cultures	
• gonorrhoea	35
• HIV prevalence	30, 31
• seroprevalence estimates for HBV and HCV	31
aspartate aminotransferase (AST)	55, 72, 76, 113
asymptomatic infections in STIs	82–3, 84
atazanavir	107
Atopobium vaginae, in bacterial vaginosis	10, 14
autoimmune hepatitis	112
autoimmune liver disease	76
azithromycin	25, 68, 81, 131, 132, 134, 141, 142, 144

B

bacterial vaginosis	10, 131
• aetiology	17
• diagnostic tests	135, 140
• microbiology	14–15
• natural history	23
• symptoms	132
• testing	83, 85
• treatment	129, 134
balanitis	88
Bartonella	66
'beats'	43
benzathine penicillin	134
benzyl benzoate	134
bilirubin	56
blood and body substance spills, management	150–1
blood-borne viruses	9, 28
• clinical assessment	34
• epidemiology	28–31
• hypermutability	15
• occupational exposure	149
• risk assessment	33
• standard precautions	147
• State and Territory notification requirements	183
• transmission	15–16, 146–7
• transmission risks	28–31, 147
• <i>see also</i> hepatitis B (HBV); hepatitis C (HCV); HIV	
blood culture, for <i>Neisseria gonorrhoeae</i>	135
blood donation, State legislation	160, 162
blood product recipients, risk of HIV, HBV and HCV	31
body composition changes, in chronic HIV infection	69
body piercing	42, 43
breastfeeding, and HCV	116
brucellosis	141
Burkitt's-like lymphomas	68

C

Campylobacter infections	10, 66
candidiasis	11, 88
• diagnosis	132
• diagnostic tests	135
• oesophageal	64, 101
• oral	65
• oropharyngeal	66
• symptoms	132, 143
• treatment	134
• vulvovaginal	65, 88, 131
CD4 cell count	17, 46, 64, 67, 100, 101–2
• and AIDS progression	101
• and antiretroviral therapy	23–4, 107
• and febrile syndrome	66
ceftriaxone	132, 134, 141, 142, 144
Cervarix, HPV vaccine	14, 25
cervical canal discharge	132
cervical cancer	14, 32–3, 64, 65
cervical diaphragms	43
cervicitis	131, 140
cervix, sampling for STIs	134
chancroid	10, 87, 133
• treatment	134
'CHAP' smear	85–6
chemotherapy, and hepatic flares	117
Chlamydia trachomatis	9, 10, 100, 132, 138
• diagnostic tests	131, 136, 137, 142
• microbiology	13
• NAAT tests	31, 32, 81, 82, 136
- specificity	84
• natural history	20
• screening	35
• serological testing	128
• State/Territory notification requirements	183
• testing for	35
- heterosexual men	82
- heterosexual women	82
- men who have sex with men	83, 84
- women who have sex with women	83
• transmission	16
• treatment	134
• <i>see also</i> genital chlamydial infections	
Chlamydia trachomatis A-C serovars	13
Chlamydia trachomatis D-K serovars	10, 13, 131, 139, 141
• epidemiology	31
• natural history	20
• treatment	134
Chlamydia trachomatis L1-L3 serovars	10, 13, 35, 133, 138
• epidemiology	32
• natural history	20–1
• serological testing	136
• treatment	134
chronic hepatitis B	111
• advanced liver disease complications	73–4
• antiviral therapy	118–19, 121–2
• clinical flares	57, 67, 73
• extrahepatic manifestations	74, 75, 76

- general management issues
 - complementary therapies..... 117
 - corticosteroid or chemotherapy effects..... 117
 - lifestyle issues..... 116
 - psychosocial support..... 117
 - routes of viral transmission..... 116
 - vaccination against HAV..... 117
- initial assessment..... 115
- investigations summary..... 78
- liver biopsy..... 77
- liver function profile..... 76
- liver transplantation..... 122
- natural history..... 71
- ongoing monitoring..... 115
- and progressive liver disease..... 73
- serological and virological markers..... 73, 75–6, 113, 114, 115
- symptoms and signs..... 34, 71–2, 73
 - by stage of disease..... 75
- who should be treated?..... 122
- *see also* hepatitis B (HBV)
- chronic hepatitis C..... 20, 111
 - advanced liver disease complications..... 73–4
 - ALT levels and presence of symptoms..... 72
 - antiviral therapy..... 72, 113–14, 118–19, 120–1
 - clinical flares..... 73
 - co-infection with HIV..... 120
 - co-infection with other hepatitis viruses..... 117
 - combined HAV and HBC vaccine..... 61
 - and early or slowly progressive liver disease..... 72–3
 - extrahepatic manifestations..... 74, 75, 76
 - general management issues
 - complementary therapies..... 117
 - corticosteroid or chemotherapy effects..... 117
 - fatigue and other symptoms..... 117
 - lifestyle issues..... 116
 - nutrition..... 116–17
 - psychosocial support..... 117
 - routes of viral transmission..... 115–16
 - vaccination against HAV and HBV..... 117
 - initial assessment..... 112
 - investigations summary..... 78
 - liver biopsy..... 77
 - liver function profile..... 76
 - liver transplantation..... 25, 122
 - monitoring for complications of liver disease..... 114
 - ongoing monitoring..... 113
 - and poor quality-of-life parameters..... 72
 - pre-referral investigation checklist..... 114
 - progression to advanced liver disease..... 74
 - serological and virological markers..... 74–6, 113
 - shared care and referral..... 114
 - symptoms and signs..... 34, 71–3
 - by stage of disease..... 75
 - who should be treated?..... 120–1
 - *see also* hepatitis C (HCV)
- chronic HIV disease *see* HIV
- chronic viral hepatitis
 - advanced liver disease complications..... 73–4
 - antiviral therapy..... 117–22
 - assessment of presence and stage of disease..... 75
 - clinical evaluation and diagnosis..... 111–12
 - clinical examination..... 77
 - early or slowly progressive liver disease..... 72–3
 - extrahepatic manifestations..... 74, 75, 76
 - general management issues..... 115–17
 - important causes..... 112
 - investigations..... 74–7
 - summary..... 78
 - liver biopsy..... 77
 - liver function profile..... 76
 - liver imaging..... 76
 - liver transplantation..... 122
 - primary care management..... 111–22
 - progressive liver disease..... 73
 - serological markers..... 74–5
 - symptoms and signs..... 54, 71–8
 - *see also* chronic hepatitis B; chronic hepatitis C
- ciprofloxacin..... 134, 142, 144
- cirrhosis..... 20, 34, 71, 72, 73, 76, 113, 114, 115, 117
- cleaning injecting equipment..... 181–2
- clinical waste..... 150
- clotting disorders..... 31
- 'clue cells', in bacterial vaginosis..... 14–15
- CMV *see* cytomegalovirus
- coliforms..... 141, 142
- Combo test (HIV Ag/Ab)..... 48
- communication between clinician and patient..... 38–9
 - barriers..... 39
- complementary therapies, HBV or HCV..... 117
- condoms..... 26, 36, 42, 43, 86, 130
- confidentiality..... 153, 155
 - State legislation..... 159
- contact dermatitis..... 143
- contact and referral information..... 175–7
- contact tracing
 - HIV, HBV and HCV..... 57, 154
 - State legislation..... 157, 159, 163–4
 - STIs..... 25, 125, 129, 141
- contaminated linen..... 150
- corticosteroids, and hepatic flares..... 117
- crabs *see* pubic lice
- criminal offences
 - disclosure of information regarding a person with or suspected of having HIV, HBV or HCV infection..... 153, 155
 - transmission of infection to another person..... 155
- cross-cultural issues
 - pre- and post-test discussion..... 96
 - sexual and/or drug history taking..... 45
- cryoglobulinaemia..... 74, 76
- cryptococcosis..... 64, 66, 68, 101
- cryptosporidiosis..... 64, 68, 101, 138
- cunnilingus *see* oral sex
- custodial settings, testing in..... 154–5
- cytomegalovirus (CMV)..... 11, 66, 67, 100
- cytomegalovirus (CMV) retinitis..... 64, 67, 101, 109

D	
dams, latex	43, 130
darunavir	107
delavirdine	106
depressive symptoms, and HIV	69, 103
dermatoses	65–6
• <i>see also</i> rashes	
diarrhoeal diseases, in HIV infections	68
didanosine	106
disclosure of information regarding a person with or suspected of having HIV, HBV or HCV infection	50, 153, 155
disseminated gonococcal infection (DGI)	34
• diagnosis	144
• rash	88
• treatment	144
DNA viruses	12–13
doctor–patient relationship	
• effective communication in	38–9
• in management of STIs	126
doctors <i>see</i> medical practitioners	
dovonanosin	10, 87, 133
• treatment	134
doxycycline	134, 141, 142
drug abuse, and HIV	103
drug fever	66
drug-induced hepatitis	55
drug interactions	108
drug use history	39–41
• checklist	39
• injecting drugs	40, 41
duty of care by medical practitioner to spouse of his/her patient	50, 153
E	
EBV <i>see</i> Epstein-Barr virus (EBV) infection	
ectopic pregnancy	20, 88, 139, 140
eczema	143
efavirenz	106
effective communication	38–9
• barriers to	39
EIA antibody test for HIV	48
employment and infectious diseases	162–3, 165, 171
emtricitabine	106
endocervical canal, swabs for STIs	135
endometriosis	88
endometritis	132
enduring powers of attorney and guardianship	172–4
enfuvirtide	107
Entamoeba histolytica	138
Entamoeba spp	11
entecavir monohydrate	24, 119, 121, 122
enteric infections	10, 11, 87, 131, 138
enteritis	
• due to STIs	139
• treatment	134
Enterobius vermicularis	10
entry inhibitors	107
epidemiology	
• acute viral hepatitis	54
• genital chlamydial infections	31–2
• genital herpes	32
• genital warts and human papillomavirus	32–3
• gonorrhoea	33
• hepatitis A (HAV)	54
• hepatitis B (HBV)	28–9, 31, 54
• hepatitis C (HCV)	28–31, 54
• HIV	28–31
• implications for Australia	30
• STIs	31–3
• syphilis	33
• trichomoniasis	33
epididymo-orchitis	20, 88, 141
• diagnostic tests	142
• treatment	142
Epstein-Barr virus (EBV) infection	11, 47, 66, 68
examination, physical in STI patients	127
exclusion from work	60
exposure-prone procedures, conducted by health care workers	149, 156
F	
faeces	
• sampling in ano-rectal syndrome	138
• sampling for STIs	135
Fallopian tubes, in PID	139
famciclovir	86, 133
fatigue, and HCV	117
fatty liver	112
febrile syndrome	34
• in HIV infected	66
fellatio <i>see</i> oral sex	
fingers, in STI transmission	16
fisting	16, 41
Fitz-Hugh Curtis syndrome	20
fixed-dose combination NRTI	106
fixed-drug eruptions	143
fluconazole	132, 134
5-fluorouracil	137
footwear	148
Fordyce spots	87
fosamprenavir	107
G	
Gardasil, HPV vaccine	14, 25–6
Gardnerella vaginalis, in bacterial vaginosis	10, 14
gatifloxacin	134
generalised rashes	88
• description and causes	143
• differential diagnosis	143
• initial treatment	144
genital chlamydia infections	125
• epidemiology	31–2
• screening	81
• treatment	129
• <i>see also</i> Chlamydia trachomatis	

- genital herpes..... 11, 88, 143
- antiviral therapy..... 25
 - epidemiology..... 32
 - natural history..... 21
 - serological testing..... 86, 128
 - transmission..... 16
 - *see also* Herpes simplex virus, types 1 and 2
- genital hygiene..... 130
- genital rashes..... 88, 135
- description and causes..... 143
 - diagnostic tests..... 143
 - differential diagnosis..... 143
 - initial treatment..... 143
- genital warts..... 11, 13, 21, 65, 87, 135–6
- epidemiology..... 32–3
 - screening..... 35
 - treatment..... 137
 - vaccination..... 25
- Giardia duodenale*..... 11, 138
- gingivitis, acute necrotising ulcerative..... 66–7
- glomerulonephritis..... 76
- glossary..... 184–9
- gloves..... 148
- gonorrhoea..... 9, 10, 14, 100, 125, 138
- diagnostic tests..... 131, 134, 135, 136, 142, 144
 - epidemiology..... 33
 - NAAT tests..... 82, 83
 - specificity..... 84
 - natural history..... 21–2
 - screening..... 35, 80
 - State/Territory notification requirements..... 183
 - symptoms..... 132, 143
 - testing
 - heterosexual men..... 82
 - heterosexual women..... 82
 - men who have sex with men..... 83
 - women who have sex with women..... 83
 - transmission..... 17
 - treatment..... 134, 141, 142
- gowns..... 148
- granulocytopenia..... 76
- group B streptococcal infection..... 132
- guardianship and enduring powers of attorney..... 172–4
- GUD *see* ano-genital ulcer disease
- H**
- haemochromatosis..... 112
- Haemophilus ducreyi*..... 10, 133
- diagnostic tests..... 136
- hand-washing..... 62, 147–8
- harm reduction..... 26, 44, 45, 62
- HAV *see* hepatitis A
- HBV *see* hepatitis B
- HCC *see* hepatocellular carcinoma
- HCV *see* hepatitis C
- HDV *see* hepatitis D (Delta)
- health care settings
- testing in..... 154–5
 - *see also* primary care settings
- health care workers
- HBV post-exposure prophylaxis..... 149
 - high-risk or exposure prone procedures..... 149, 150, 156
 - HIV post-exposure prophylaxis..... 150
 - infected..... 150, 156
 - low-risk procedures..... 149
 - occupational exposures..... 51, 149
 - risk estimates for HIV, HBV and HCV..... 31
 - testing..... 149
 - vaccination..... 148–9
 - variable-risk procedures..... 149
- health promotion
- for HIV..... 103–5
 - for STIs..... 129, 130
- hepatic coagulopathy..... 57, 59
- hepatic encephalopathy..... 57, 59, 72, 74
- hepatic ‘flares’..... 57, 67, 72, 73, 113, 117
- hepatitis
- acute *see* acute viral hepatitis
 - alcoholic..... 55
 - autoimmune..... 54, 112
 - chronic *see* chronic viral hepatitis
 - contact and referral information sources..... 176
 - drug-induced..... 55
- hepatitis A (HAV)..... 11, 87, 138
- acute..... 54–62
 - and acute liver failure..... 57
 - co-infection with other hepatitis viruses..... 117
 - diagnostic clues..... 56
 - epidemiology..... 54
 - exclusion from work..... 60
 - exposed person’s immunity..... 60
 - hand-washing to prevent transmission..... 62
 - incubation periods..... 54
 - infection in MSM..... 129
 - outcomes..... 54, 55
 - persons for whom vaccination is recommended..... 61
 - post-exposure follow-up..... 61
 - post-exposure prophylaxis..... 60
 - precautions for preventing transmission..... 147
 - screening test..... 85
 - serological testing..... 56, 57, 128, 138–9
 - treatment..... 56
 - vaccination..... 25, 61, 129, 130, 149
- hepatitis B (HBV)..... 9, 11, 91, 125
- acute..... 54–62
 - and acute liver failure..... 57
 - adult-acquired..... 71
 - affect on people..... 179
 - antiviral therapy..... 24, 56–7, 118–19, 121–2
 - and anxious patient management, case study..... 59
 - co-infection with HIV..... 20, 48, 67, 121
 - contact tracing..... 154
 - diagnostic clues..... 56
 - disclosure of information about a person with/ suspected with HBV..... 155
 - epidemiology..... 28–9, 31, 54
 - exclusion from work..... 60
 - exposed person’s immunity..... 60
 - incubation periods..... 54
 - in injecting drug users..... 29, 116

- natural history..... 18–20, 71, 179
 - number of people with..... 179
 - outcomes..... 54, 55
 - patient information..... 179
 - perinatal transmission..... 29, 35, 61, 71
 - persons for whom vaccination is recommended..... 61
 - phobia..... 96
 - post-exposure follow-up..... 62
 - post-exposure prophylaxis..... 60
 - in health care setting..... 149
 - post-test discussion..... 93–5
 - pre-test discussion..... 92–3
 - prevention
 - of perinatal transmission 61
 - of transmission..... 36, 147, 179
 - replicase enzymes..... 15
 - screening test..... 85
 - serological testing..... 24, 56, 75–6, 113, 128
 - State/Territory notification requirements..... 183
 - testing..... 82, 83, 90, 91
 - transmission..... 15, 116, 179
 - factors associated with increased/decreased..... 36
 - transmission risk..... 29
 - treatment..... 24, 56–7, 118–19, 121–2
 - vaccination..... 36, 61–2, 116, 129, 130, 148–9
 - virological tests..... 20, 24, 76, 113
 - virolog..... 12–13
 - *see also* chronic hepatitis B
- hepatitis B immunoglobulin (HBIG)..... 60, 61**
- hepatitis C (HCV)..... 9, 11, 125**
- acute..... 54–62
 - antiviral therapy..... 24–5, 72, 113–14, 118–19, 120–1
 - co-infection with HIV..... 15, 20, 48, 67, 101, 104, 120
 - contact tracing..... 154
 - diagnostic clues..... 56
 - disclosure of information about a person with/ suspected with HCV..... 155
 - epidemiology..... 28–31, 54
 - exclusion from work..... 60
 - incubation periods..... 54
 - in injecting drug users..... 29, 32, 116
 - liver biopsy..... 77
 - natural history..... 19, 20, 180
 - outcomes..... 54, 55
 - perinatal transmission..... 16, 29
 - phobia..... 96
 - post-exposure follow-up..... 62
 - post-exposure prophylaxis..... 60
 - post-test discussion..... 93–5
 - pre-test discussion..... 92–3
 - prevention of transmission..... 36, 147
 - replicase enzymes..... 15
 - serological testing..... 56, 57, 74–5, 113, 128, 136
 - State/Territory notification requirements..... 183
 - sustained virological remission..... 24–5
 - testing..... 90, 91
 - in pregnancy..... 97
 - transmission..... 15–16, 29, 115–16, 180
 - factors associated with increased/decreased... 36
 - transmission risk..... 29, 30, 31
 - treatment..... 24–5, 72, 113–14, 118–19, 120–1
 - virological testing..... 57, 61, 75–6, 113
 - virology..... 13
 - *see also* chronic hepatitis C
- hepatitis D (Delta) (HDV), virological markers..... 113**
- hepatocellular carcinoma (HCC)..... 19, 24, 72, 73, 76, 114, 117–18**
- Herpes simplex mucocutaneous ulcer..... 64**
- Herpes simplex virus, types 1 and 2..... 11, 13, 32, 34, 88, 125, 131, 138**
- diagnostic tests..... 133, 136
 - natural history..... 21
 - and risks of HIV..... 23, 64, 86
 - screening..... 35
 - serological testing..... 86, 128
 - State/Territory notification requirements..... 183
 - symptoms..... 87, 143
 - testing..... 35, 83
 - transmission..... 16
 - treatment..... 86, 134
 - virology..... 13
- Herpes varicella zoster..... 101, 133**
- heterosexual men**
- seroprevalence estimates for HIV, HBV and HCV... 31
 - sexual health check..... 82
- heterosexual women**
- seroprevalence estimates for HIV, HBV and HCV... 31
 - sexual health check..... 82
- high-risk procedures, conducted by health care workers..... 149, 150, 156**
- high vaginal swabs, for STIs..... 127, 132, 135**
- Histoplasma..... 66**
- history taking..... 38–45, 92**
- *see also* risk assessment
- HIV..... 9, 11, 125, 178**
- affect on people..... 178
 - and AIDS-related illness..... 109
 - anti-discrimination..... 155–6
 - antiretroviral therapy..... 23–4, 49, 103, 105–9
 - anxiety and sexual identity..... 96
 - assessment and monitoring..... 100, 104
 - CD4 cell count..... 17, 46, 64, 67, 100, 101–2, 107
 - chronic..... 63–9
 - clinical conditions suggestive of..... 65
 - clinical latency..... 64
 - co-infection
 - with HBV..... 20, 48, 67, 101
 - with HCV..... 15, 20, 48, 67, 101, 104, 120
 - with HSV..... 23, 64, 86
 - with STIs..... 23, 32, 35–6, 52, 104, 126–7
 - contact and referral information sources..... 175–6
 - contact tracing..... 49, 154
 - diagnostic tests..... 144
 - differential diagnosis..... 63
 - disclosure of information about a person with/ suspected with HIV..... 153, 155
 - epidemiology..... 28–31
 - health promotion..... 103–5
 - immune-based therapies..... 24, 109
 - immunological and virological status..... 101
 - in Indigenous Australians..... 95

- initial assessment.....100–1
 - checklist.....100
 - legal responsibilities.....152–6
 - management as chronic disease.....99–100
 - markers and risk of progression to AIDS.....101–2
 - Models of Care.....102
 - monitoring infection.....102
 - natural history.....17–18, 100, 178
 - notification of third parties.....153
 - number of people with.....178
 - opportunistic infections.....101, 108
 - patient education.....105
 - patient information.....178
 - perinatal transmission.....29
 - phobia.....96
 - post-exposure prophylaxis (non-occupational). 48, 50, 51, 105
 - post-exposure prophylaxis (occupational).....150
 - post-test discussion.....69, 90, 93–5
 - pre-test discussion.....91, 92–3
 - prevention of transmission.....36, 103–5, 147, 178
 - primary care management.....99–110
 - primary infection.....46–52, 64–6
 - prophylaxis.....109
 - psychological assessment.....103
 - psychosocial support.....49–51, 69, 102–3
 - rash.....88, 143
 - relationship issues.....103
 - replicase enzymes.....15
 - resources for health care professionals and positive people.....105
 - and risk of progression to AIDS.....101
 - serological testing.....128, 136
 - State/Territory notification requirements.....183
 - and substance abuse.....103
 - support systems.....103
 - symptoms and signs of chronic infection..34, 63–9, 100
 - cough and fever, case study.....30
 - distinguishing from flu-like symptoms...47, 50, 109
 - testing.....81, 90, 91–2, 96
 - during pregnancy.....85, 96–7
 - therapies.....23–4, 49, 103, 105–9
 - transmission.....15, 29, 178
 - factors associated with increased/decreased..36
 - transmission risk.....29, 31
 - treatment.....100, 105–9, 144
 - treatment regimens.....106–8
 - viral load.....46, 101, 102, 103, 104
 - virology.....12
 - *see also* primary HIV infection
- homosexual men *see* men who have sex with men**
- HPV *see* human papillomavirus**
- HSV *see* Herpes simplex virus, types 1 and 2**
- human herpesvirus type 8 (HHV-8).....64**
- human immunodeficiency virus *see* HIV**
- human papillomavirus (HPV).....11, 65, 87, 125, 130, 136, 138**
- antiviral therapy.....25
 - epidemiology.....32–3
 - natural history.....21
 - screening.....35
 - squamous intraepithelial lesions...11, 14, 21, 35, 65, 86
 - State/Territory notification requirements.....183
 - testing.....83
 - transmission.....16–17
 - vaccination.....14, 25–6
 - virology.....13–14
- hypergammaglobulinaemia.....65**
- hypersplenism.....76**
- hypoalbuminaemia.....74, 76, 113**
- I**
- illicit drugs, common names.....40**
- imiquimod, treatment for warts.....137**
- immune-based therapies (for HIV).....24, 109**
- immune reconstitution disease.....67**
- immunisation *see* vaccination**
- immunodeficiency**
- mild.....64
 - severe.....67
- Indigenous Australians**
- HIV in.....95
 - pre- and post-test discussion.....95
 - seroprevalence estimates for HIV, HBV and HCV...31
 - sexual health check
 - heterosexual men.....82
 - heterosexual women.....82
 - STIs in.....87, 95, 128
 - syphilis in.....33
 - trichomoniasis in.....33
- indinavir.....107**
- infected health care workers.....150, 156**
- infection control guidelines.....146–51**
- gloves.....148
 - hand hygiene.....147–8
 - for the health care setting.....150
 - legal and ethical issues.....151
 - management of blood and body substance spills..150–1
 - needlestick or sharps injury prevention.....148
 - personal protective equipment.....148
 - transmission of blood-borne viruses.....146–7
 - vaccination of health care workers.....148–9
- infectious mononucleosis.....11**
- influenza, distinguishing from primary HIV...47, 50, 109**
- information resources**
- about HIV.....105
 - about STIs.....129, 130
- injecting drug-use history.....41**
- injecting drug-users**
- equipment and language.....40
 - risk of HIV, HBV and HCV.....29, 32, 116
 - safe injecting procedures.....40
 - safer injecting and cleaning injecting equipment....181–2
- injecting equipment**
- cleaning, patient information.....181–2
 - disposal, health care setting.....150
 - safer injecting, patient information.....181
- interferon alfa-2a.....24, 118**
- interferon alfa-2b.....118**
- interleukin-2.....24**
- isopsoriasis.....64**

J

joint aspirate, for *Neisseria gonorrhoeae* 135

K

Kaposi's sarcoma 11, 64–5, 101

Klebsiella granulomatis 10, 133

L

lamivudine 24, 106, 118, 121, 122

laryngeal papillomatosis 17

laws by State and Territory 157–74

legal issues

- anti-discrimination 155–6
- confidentiality 153, 154
- contact tracing 154
- criminal law 155
- duty of care 153
- infection control 151
- notification of third parties 153–4
- pre-test discussion for HIV 92
- provision of information to the patient 152–3
- in relation to HIV and viral hepatitis 152–74
- testing in health care or custodial settings 154–5

lesbian women *see* women who have sex with women

leucopenia 74

leucorrhoea 132

LGV *see* lymphogranuloma venereum

lichen planus 74, 76, 88, 143

lichen sclerosus 88, 143

lifestyle issues, and HCB or HCV 116

lipodystrophy syndrome 108

liver biopsy 77, 114

liver disease 20, 34, 71, 114, 115

- early or slowly progressive 72–3
- end-stage 25
- and malnutrition 117
- progressive 72, 73

liver enzymes *see* alanine aminotransferase (ALT);

aspartate aminotransferase (AST)

liver failure 20, 34, 54, 57, 71, 72, 117

- management 59
- symptoms and signs 74

liver function 179

liver function tests 57, 76

liver imaging 76

liver transplantation 25, 122

lopinavir 107

low-risk procedures, conducted by health care workers 149

lymphadenopathy 65

lymphogranuloma venereum (LGV) 10, 13,

16, 87, 133, 138

- co-infection with HIV 104
- diagnostic testing 128, 138
- epidemiology 32
- natural history 20–1
- treatment 134

lymphoma 64, 66, 68, 101

lymphopenia 65

lymphocytosis, atypical 56

M

MAC *see* *Mycobacterium avium* complex

medical practitioners

- collection of contact tracing information 154
- duty of care to spouse of his/her patient 153

men who have sex with men (MSM) 42, 43

- ano-rectal Pap smear 85–6
- ano-rectal syndromes 87
- chlamydial infections 32
- genital herpes 32
- gonorrhoea in 33
- LGV in 16, 87
- pre- and post-test discussion 91
- seroprevalence for HIV, HBV and HCV 29, 31
- sexual health check 83
- STIs 10, 11
- syphilis in 8
- testing
 - for HAV 85
 - for HIV 85
 - for STIs 35, 128

meningitis, aseptic 65

metronidazole 132, 141

microsporidiosis 10, 68, 101

Mobiluncus sp. in bacterial vaginosis 10, 14

molluscum contagiosum 11, 87, 135, 136

- and chronic HIV infection 65
- treatment 137–8

mononeuritis 76

mononucleosis syndrome, atypical 65

mouth ulcers 66

Mycobacterium avium complex (MAC) 64, 66, 67,

68, 101, 109, 138

Mycoplasma genitalium 10, 131, 141, 142

- diagnostic tests 136

Mycoplasma hominis 10, 141, 142

N

NAATs *see* nucleic acid amplification tests (NAATs)

National Hepatitis C Testing Policy 2007 90

National HIV Testing Policy 2006 90

natural history

- bacterial vaginosis 23
- *Chlamydia trachomatis* 20–1
- hepatitis B (HBV) 18–20, 71, 179
- hepatitis C (HCV) 19, 20, 180
- Herpes simplex virus, types 1 and 2 21
- HIV 17–18, 100, 178
- human papillomavirus 21
- *Neisseria gonorrhoeae* 21–2
- STIs 20–3, 126
- *Treponema pallidum* 22–3
- *Trichomonas vaginalis* 23

needlestick injury

- occupational exposure hotline 51, 149
- prevention 148
- and risk of HIV, HBV and HCV 29

- Neisseria gonorrhoeae** 10, 131, 138, 139, 141, 142
- blood culture 135, 144
 - joint aspirate 135
 - microbiology 14
 - natural history 21–2
 - rectal mucosal swabs 136
 - throat swab 136
 - transmission 17
 - urethral discharge 136
- Neisseria meningitidis** 10, 131
- nelfinavir** 107
- neoplastic disease** 132
- neurological symptoms, in chronic HIV infection** 68
- neutropenia** 65
- nevirapine** 106
- non-Hodgkin's lymphoma** 64, 65, 68, 101
- non-nucleoside reverse transcriptase inhibitors (NNRTI)** 23, 106, 107
- non-occupational exposures**
- post-exposure prophylaxis (NPEP) 48, 50, 51, 105
 - risk assessment 51
- non-specific urethritis** 131
- notification of third parties** 153–4
- notification/notifiable diseases** 59
- State legislation 157, 159, 161–2, 163, 166, 167, 168, 170, 183
- nucleic acid amplification tests (NAATs)** 31, 32, 81, 84
- specificity for chlamydia and gonorrhoea 84
- nucleoside/nucleotide analogue reverse transcriptase inhibitors (NRTI)** 23, 106, 108
- drug interactions 108
- nutrition, and HCV** 116–17
- O**
- obesity, and HCV** 117
- occupational exposures**
- health care workers 51, 149
 - post-exposure prophylaxis 149–50
 - risk of HIV, HBV and HCV 29
- oesophageal candidiasis** 64, 101
- oesophageal varices** 74
- opportunistic infections** 101, 108
- oral hairy leukoplakia** 66, 101
- oral sex** 29, 36, 41, 43
- oro-anal sex (rimming)** 41
- oropharyngeal candidiasis** 10, 66
- ovarian cyst** 88
- overweight, and HCV** 117
- P**
- P24 antigen test (for HIV)** 48
- palmar erythema** 34
- Pap smear** 26, 33, 35, 65, 135, 136
- partner notification** *see* **contact tracing**
- patient assessment with a possible STI**
- co-infection with HIV 126–7
 - initial assessment 126
 - natural history and transmission of HCV 180
 - physical examination 127
 - quick psychosocial assessment 128
 - serological testing 128
 - taking tests 127
- patient information**
- HIV infection 105
 - natural history and transmission of HBV 179
 - natural history and transmission of HIV 178
 - safer injecting and cleaning injecting equipment 181–2
- patients with disabilities, harm reduction and safe sex practices** 45
- pearly penile papules** 87, 136, 137
- pegylated interferon alfa-2a monotherapy** 57, 119, 121
- pegylated interferon alfa-2a plus ribavirin** 24, 118
- pegylated interferon alfa-2b plus ribavirin** 118
- pelvic inflammatory disease (PID)** 20, 23, 88, 125, 139
- clinical features suggesting non-STI causes 140
 - common characteristics in STIs 140
- pelvic pain syndrome in women** 88
- description and causes 139
 - diagnostic tests 140
 - differential diagnosis 139–40
 - initial treatment of STI-related 141
 - ongoing treatment for specific STIs 141
- perinatal transmission**
- HBV 29, 35, 61, 71
 - HCV 16, 29
 - HIV 29
- peripheral neuropathy** 76
- permethrin** 134
- personal protective equipment** 148
- pharyngeal infections with chlamydia or gonorrhoea** 10, 66
- plastic aprons** 148
- pneumococcal pneumonia** 109
- Pneumocystis jiroveci pneumonia** 30, 64, 66, 67–8, 101, 109
- pneumonia** 64, 65, 66
- podophyllotoxin, treatment for warts** 137
- polyarteritis nodosa** 76
- polyarthralgia, in DGI** 88
- polymerase chain reaction (PCR) test** 31, 56, 81
- porphyria cutanea tarda (PCT)** 74, 76
- portal hypertension** 74, 76
- post-exposure prophylaxis (PEP)**
- in health care setting 149
 - HBV 150
 - HIV 150
 - non-occupational, HIV 48, 50, 51, 105
 - in pregnancy 96–7
- post-test discussion** 69, 90, 93–5
- cross-cultural issues 96
 - discussion process 91
 - giving a negative result 94–5
 - giving a positive result 93–4
 - indeterminate results 95
 - in Indigenous Australians 95
- pre-test discussion** 90, 92–3
- changes to terminology 90
 - cross-cultural issues 96
 - discussion process 91
 - HIV summary 91
 - in Indigenous Australians 95
 - issues to cover 92

- coping with a positive result	93	progressive multifocal leukoencephalopathy	64, 68
- implications of an indeterminate result	93	prostitution, State legislation	158, 166, 170, 171
- implications of a negative result	93	protease inhibitors	23, 107, 108
- implications of a positive result	92–3	• drug interactions.....	108
- information about prevention	92	• side effects.....	69
- medical consequences of infection	92	protective eyewear	148
- referral	93	provision of information to the patient	152–3
- supporting person while waiting for the result	93	Pseudomonas sp	141
- window period	93	psoriasis	65, 66, 88, 101, 143
• objectives	92	psychiatric patients, harm reduction and safe sex practices	45
• in pregnancy	96–7	psychological assessment, HIV infection	103
pregnant women		psychosexual history	126
• HCV testing	97	psychosocial support	
• HIV pre- and post-test discussion	96–7	• acute viral hepatitis.....	61
• HIV testing	85, 96	• chronic viral hepatitis.....	117
• reasons for testing	96	• HIV patient.....	49–51, 69, 102–3
prevention		• STIs.....	128
• acute viral hepatitis	59, 61–2	Pthirus pubis	10
• and harm reduction messages	26, 44	pubic lice	10, 88
• HBV	25, 36, 61, 179	• symptoms.....	143
• HCV	36, 147	• treatment.....	129, 134
• HIV	36, 103–5, 178	public health orders, State legislation	160, 163–4, 166–8
• sharps injuries	148		
• STIs	36, 130		
• <i>see also</i> condoms; sexual health checks; vaccination			
Prevotella sp, in bacterial vaginosis	14	R	
primary care management		rapid plasma regain (RPR) test	81
• chronic viral hepatitis	111–22	rashes	
• HIV disease	99–110	• ano-genital.....	135
primary care settings		• and chronic HIV infection.....	65–6, 88, 143
• antiviral therapy for HCV.....	121	• generalised.....	88, 143–4
• infection control.....	150	• genital.....	88, 143
• management of blood and body substance spills.....	150–1	• secondary syphilis.....	143
• testing for STIs	83	• specific treatment for STI-related.....	144
primary central nervous system lymphomas (PCNSL)	68	rectal mucosa, swabs for STIs	135–6
primary HIV infection	46–52	retained foreign bodies	132
• acute retroviral syndrome.....	46–7	retroviral syndrome, acute	46–7, 50
• antibody tests.....	48	re-usable equipment, sterilisation/disinfection	150
• antigen tests.....	48	reverse transcriptase polymerase chain reaction (RT PCR)	48
• antiretroviral therapy.....	49	ribavirin	24, 118
• clinician's role.....	51	• side effects.....	121
• contact tracing.....	49	rimming <i>see</i> oro-anal sex	
• distinguishing from severe flu.....	47, 50, 109	risk assessment	39–45, 92
• investigations.....	48	• for blood-borne virus.....	33
• management.....	48–51	• drug-use history.....	39–41
• pathogenesis.....	46	• general medical history.....	39
• psychosocial support for newly diagnosed patients	49–51	• injecting drug-use history.....	41
• recent risk exposure.....	48	• non-disclosure of high-risk sexual activity, case study.....	30
• and risk of other STIs.....	52	• prevention and harm reduction messages.....	44
• support services.....	51	• sexual history.....	41–4
• symptoms and signs.....	47, 64–6	• for STIs.....	33–4
primary syphilis <i>see</i> syphilis		ritonavir	107
privacy	153	RNA viruses	12, 13
• Commonwealth legislation.....	157	rural and remote communities	
• State legislation.....	158	• sexual health check	
proctitis		- heterosexual men.....	82
• due to STIs.....	139	- heterosexual women.....	82
• rectal mucosa examination.....	138		
progressive liver disease	73		
• early or slowly progressive.....	72–3		

S

- safe-sex practices 50, 127
- tips on 44
- safer injecting 40, 181
- Salmonella infections 10, 66
- salmonellosis 64, 87
- salpingitis 139
- saquinavir 107
- Sarcoptes scabiei 10
- scabies 10, 87, 135
- symptoms 143
 - treatment 129, 134
- screening
- for HAV and HBV 85
 - for STIs 34–5, 80, 81
 - *see also* testing
- scrotal swelling 99
- description and causes 141
 - diagnostic tests 142
 - differential diagnosis 141
 - initial treatment of STI-related 142
 - ongoing treatment for specific STIs 142
- seborrhoeic dermatitis 66, 101
- secondary syphilis *see* syphilis
- septicaemia 66
- seroconversion illness, HIV 46–7, 50
- serological testing
- Chlamydia trachomatis 128, 136
 - hepatitis A 56, 57, 128, 136
 - hepatitis B 56, 57, 73, 75, 128, 136
 - hepatitis C 56, 57, 74–5, 113, 128, 136
 - herpes simplex (type specific) 86, 128
 - HIV 128, 136
 - LGV 136
 - syphilis 128, 136
- sex-on-premises venues (SOPV) 43
- sex toys 16, 41, 43
- sex workers 32, 35, 42, 43
- sexual and/or drug history taking 38–45, 92
- cross-cultural issues 45
 - effective communication 38–9
 - patients with disabilities or psychiatric problems 45
 - physical environment 38
 - prevention and harm reduction messages 44
 - *see also* risk assessment
- sexual assault 35
- sexual health checks
- encouraging patients to have 36, 44
 - heterosexual men 82
 - heterosexual women 82
 - how often to test? 86
 - men who have sex with men (MSM) 83
 - women who have sex with women (WSW) 83
- sexual history 41–4, 126, 139–40
- checklist 43
 - condom usage 42, 43
 - purpose 41
 - questions to ask 41–3
 - risk assessment 42, 43
- sexually transmitted infections *see* STIs
- sharps disposal 150
- sharps injury prevention 148
- shigellosis 87, 138
- Sjogren's syndrome 78
- skin rashes *see* rashes
- spider naevi 34
- splenomegaly 34
- squamous intraepithelial lesion due to HPV 11, 65
- high-grade lesions (HSIL) 14, 21, 35, 86
 - low-grade lesions (LSIL) 21
- standard precautions, blood-borne virus transmission 147
- Staphylococcus aureus (toxic shock syndrome) 132
- State/Territory notification requirements
- for blood-borne viruses and STIs 183
 - legislation 157, 159, 161–2, 163, 166, 167, 168, 170
- stavudine 106
- sterile equipment 150
- sterilisation systems 150
- STI syndromes 86–8, 126, 130–44
- STIs 9, 10–11
- asymptomatic infection 82–3, 84
 - atypical transmission 33
 - clinical assessment 34
 - co-infection with HIV 23, 32, 35–6, 52, 104, 126–7
 - compliance with treatment regimens 129
 - contact and referral information sources 176–7
 - contact tracing 25, 125, 129
 - diagnostic tests 131, 133, 134, 135, 136–7, 138–9
 - doctor-patient relationship 126
 - epidemiology 31–3
 - health promotion 129, 130
 - in Indigenous Australians 33, 95, 128
 - information resources 130
 - management challenges 125–6
 - misconceptions about 125
 - natural history 20–3, 126
 - patient assessment 126–8
 - populations at risk 10–11
 - presumptive diagnosis 128–9
 - prevention strategies 36, 130
 - primary care management 125–44
 - risk assessment 33–4
 - screening 35–6, 80, 81
 - serological testing 128, 136
 - and sexual health risk of HIV 35–6
 - State/Territory notification requirements 183
 - symptoms and signs 86–8, 126, 130–44
 - testing for 80–8
 - criteria 81
 - heterosexual men 82
 - heterosexual women 82
 - how often to test? 86
 - men who have sex with men 83
 - in primary care 83
 - who to test? 83–4
 - women who have sex with women 83
 - transmission 10–11, 16–17
 - factors associated with increased/decreased 36
 - treatment 25, 129, 131, 134
 - vaccination 129
 - what are they? 125
 - *see also* specific diseases, eg. syphilis

substance abuse, and HIV	1–3	• State/Territory notification requirements	183
suicidal ideation, and HIV	103	• tertiary	22, 23
support services, primary HIV infection	51	• testing	81
swabs for STIs		- heterosexual men	82
• ano-genital rash	135	- heterosexual women	82
• ano-genital ulcers or lesions	136	- men who have sex with men	83
• blind ano-rectal	127	- women who have sex with women	83
• endocervical canal	135	• TPPA test	81
• high vaginal	127, 132, 135	• transmission	17
• rectal mucosa	135–6, 138	• treatment	129, 133, 134, 144
• self collected	127		
• throat	136		
• urethral discharge	136		
symptoms and signs of chronic HIV	47, 63–9	T	
• ano-genital warts and squamous dysplasia	65	tattooing	29, 42
• body composition changes	69	tenofovir	106, 122
• clinical latency	64	tenosynovitis, in DGI	88
• dermatoses	65–6	testicular cancer	88, 141, 142
• diarrhoeal diseases	68	testicular torsion	88, 141, 142
• febrile syndrome	66	testing	
• hepatitis co-infection	67, 101, 104, 120, 121	• asymptomatic	82–3, 84
• herpes simplex	64	• context of	90–1
• immune reconstitution disease	67	• in custodial settings	154–5
• Kaposi's sarcoma	64–5	• for HBV	90, 91
• mild immunodeficiency	64	• for HCV	90, 91
• molluscum contagiosum	65	• in health care settings	154–5
• Mycobacterium avium complex	68	• for HIV	90, 91–2, 96–7
• neurological conditions	68	• indirect requests for	92
• non-Hodgkin's lymphoma	68	• legal requirements	92
• oral conditions	66–7	• post-test discussion	90
• Pneumocystis jiroveci pneumonia	67–8	• pre-test discussion	90, 91
• severe immunodeficiency	67	• and pregnant women	96–7
• shingles	64	• reasons for	91–2
symptoms and signs of primary HIV infection	64	• requests for	96
• immune activation symptoms	64	• for STIs	34–5, 80–8, 128, 131, 133, 134, 135, 136, 136–7, 138–9
symptoms and signs of STI syndromes	86–8, 126, 130–44	- in primary care settings	83, 84
• ano-genital lumps and bumps	87, 135–7	- tests to use and rationale for using them	84–5
• ano-genital ulcer disease	87, 133–5	• <i>see also</i> screening; serological testing	
• ano-rectal syndromes	87, 138–9	thread worms	10
• pelvic pain syndrome in women	88, 139	throat swab, for gonorrhoea	136
• scrotal swelling	88, 141–2	thrombocytopenia	65, 74, 76, 113
• skin rashes, genital or generalised	88, 143–4	thrush	
• urethral discharge	86, 130–1	• oral	65
• vaginal discharge	87, 131, 132–3	• vaginal	65, 131
syphilis	9, 10, 14, 100, 125	thyroid disorders	74, 76
• co-infection with HIV	104	thyroid function tests	76
• diagnostic tests	133, 138, 144	tinidazole	132, 134
• epidemiology	33	tipranivir	107
• in Indigenous Australians	33	toxic shock syndrome	132
• late	22	toxoplasmosis	64, 66, 68, 100, 101, 109
• latent ('early')	22	trachoma	13
• natural history	22–3	transfer of human tissue, State legislation	160–1, 171
• prevalence	128	transmission	
• primary	22, 23, 87, 134	• blood-borne viruses	15–16, 146–7
• rash	88	• Chlamydia trachomatis	16
• RPR test	81, 84	• hepatitis A	62
• screening	35	• hepatitis B	15, 116, 179
• secondary	22, 23, 34, 87, 88, 134, 136, 138, 143, 144	• hepatitis C	15–16, 115–16, 180
• serological testing	128, 136, 139	• herpes simplex virus, types 1 and 2	16
• serology	22	• HIV	15, 36, 178
• stages in adults	22	• human papillomavirus	16–17
		• offences	155, 158–9, 161, 165, 167, 168, 170, 171

- STIs 10–11, 16–17, 36
 - syphilis 17
 - *Trichomonas vaginalis* 27
 - transmission risks**
 - of blood-borne viruses 28–31, 147
 - hepatitis B 29, 31
 - hepatitis C 29, 30, 31
 - HIV 29, 31
 - travellers, hepatitis vaccination** 62
 - Treponema pallidum*** 10, 133, 138
 - diagnostic tests 136
 - microbiology 14
 - natural history 22–3
 - transmission 17
 - Treponema pallidum* particle agglutination (TPPA)** 81
 - Trichomonas vaginalis*** 10, 131
 - microbiology 14
 - NAATs 81
 - natural history 23
 - transmission 27
 - trichomoniasis** 10
 - diagnostic tests 135, 136, 142
 - epidemiology 33
 - in Indigenous Australians 33
 - screening 35, 81
 - State/Territory notification requirements 183
 - symptoms 132, 143
 - treatment 129, 134, 142
 - tuberculosis** 65, 66, 100, 109, 141
- U**
- Ureaplasma urealyticum*** 10, 131, 141, 142
 - urethral discharge** 86
 - description and causes 130–1
 - diagnostic tests 131, 136
 - differential diagnosis 131
 - initial treatment 131
 - STI causes 131
 - treatments for specific STIs 131, 134
 - urethritis** 10, 14, 131, 141
 - adenoviral 11
 - urine**
 - first catch (FCU) 127, 136
 - mid-stream (MSSU) 127, 136
- V**
- vaccination**
 - chronic hepatitis C patients with HAV and HBV 117
 - health care workers 148–9
 - hepatitis A 25, 61, 117, 129, 130, 149
 - hepatitis B 25, 36, 61–2, 116, 117, 129, 130, 148–9
 - travellers 62
 - vaginal candidiasis** 65, 88, 131
 - vaginal discharge** 87
 - description and causes 132
 - diagnostic tests 132
 - differential diagnosis 132
 - initial treatment 132–3
 - STI causes 131
 - treatments for specific STIs 133, 134
 - vaginal thrush** 65
 - vaginitis** 14, 131
 - valaciclovir** 86, 133, 134
 - variable-risk procedures, conducted by health care workers** 149
 - varicella-zoster virus** 101, 133
 - viral hepatitis**
 - acute *see* acute viral hepatitis
 - chronic *see* chronic viral hepatitis
 - legal responsibilities 152–6
 - *see also* hepatitis A (HAV); hepatitis B (HBV); hepatitis C (HCV)
 - viral load** 46, 102, 103, 104
 - and AIDS progression 101
 - virology**
 - HBV 12–13
 - HCV 13
 - HIV 12
 - HPV 13–14
 - HSV 13
 - vulvovaginal candidiasis** 65, 88, 131
 - treatment 129
- W**
- Western Blot (HIV antibodies)** 48
 - Wilson's disease** 76, 112
 - women with HIV, family and children issues** 49, 103
 - women who have sex with women (WSW)** 43
 - seroprevalence for HIV, HBV and HCV 29, 31
 - sexual health check 83
 - testing for bacterial vaginosis 85
 - work, exclusion from** 60
- Y**
- Yersinia enterocolitica*** 10
- Z**
- zidovudine** 106